In lung cancer, for example, a study of 5,688 patients with non–small-cell lung cancer from 2011 to 2016 demonstrated that 15.4% received broad-based genomic sequencing and 84.6% received single gene testing for EGFR and/or ALK. This evidence concerns the gene EGFR and lung cancer.